Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

Neil P. Shah,Valentín García-Gutiérrez,Antonio Jiménez-Velasco,Sarah Larson,Susanne Saussele,Delphine Rea,François-Xavier Mahon,Moshe Yair Levy,María Teresa Gómez Casares,Fabrizio Pane,Franck-Emmanuel Nicolini,Michael J. Mauro,Oumar Sy,Patricia Martin-Regueira,Jeffrey Howard Lipton

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

2019

Neil P. Shah
Valentín García-Gutiérrez
Antonio Jiménez-Velasco
Sarah Larson
Susanne Saussele
Delphine Rea
François-Xavier Mahon
Moshe Yair Levy
María Teresa Gómez Casares
Fabrizio Pane
Franck-Emmanuel Nicolini
Michael J. Mauro
Oumar Sy
Patricia Martin-Regueira
Jeffrey Howard Lipton

AbstractTreatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is considered a feasible option, especially with the ability of second-generation tyrosine...

Keywords:

Oncology
Myeloid leukemia
Dasatinib
Imatinib
Diabetes mellitus
Discontinuation
Molecular Response
Immunology
Chronic phase chronic myeloid leukemia
Medicine
Internal medicine
Tyrosine
in patient
Cancer research
Tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations